You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

212 Results
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
Oct 2025
Regimen
Cancer Type:
Genitourinary, 
Penile
Intent: Adjuvant, Curative
Funding:
ODB - General Benefit
    capecitabine
New
Jan 2026
Regimen
Intent: Curative, Adjuvant
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
New
Jan 2026

Pages